Basically the Hexima antifungal treatment failed the phase 2b trial and the results didn't justify continued research.
https://www.biotechdaily.com.au/wp/wp-content/uploads/2022/07/BD-Biotech-Daily-Jul-11-Hexima.pdf
- Forums
- ASX - By Stock
- 1AI
- Ann: Appointment of Chief Scientific Officer
Ann: Appointment of Chief Scientific Officer, page-16
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 7185695 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 1696938 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 7185695 | 0.007 |
12 | 5566749 | 0.006 |
7 | 6410009 | 0.005 |
4 | 4065000 | 0.004 |
2 | 4590000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 1696938 | 12 |
0.009 | 2275277 | 11 |
0.010 | 2493145 | 4 |
0.011 | 1490400 | 3 |
0.012 | 363666 | 3 |
Last trade - 14.21pm 10/09/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |
Day chart unavailable